tradingkey.logo
tradingkey.logo

NovaBay Pharmaceuticals Inc

NBY
View Detailed Chart
1.374USD
-0.156-10.18%
Close 03/30, 16:00ETQuotes delayed by 15 min
1.29KMarket Cap
LossP/E TTM

NovaBay Pharmaceuticals Inc

1.374
-0.156-10.18%
Intraday
1m
30m
1h
D
W
M
D

Today

-10.18%

5 Days

+18.47%

1 Month

-4.57%

6 Months

-82.38%

Year to Date

-95.13%

1 Year

-31.61%

View Detailed Chart

Key Insights

NovaBay Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 125 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 0.85.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NovaBay Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
125 / 157
Overall Ranking
468 / 4542
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

NovaBay Pharmaceuticals Inc Highlights

StrengthsRisks
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -0.39, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.14M shares, increasing 33.79% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 365.85K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.07.

Analyst Rating

Based on 0 analysts
--
Current Rating
0.850
Target Price
-18.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

NovaBay Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

NovaBay Pharmaceuticals Inc Info

NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Ticker SymbolNBY
CompanyNovaBay Pharmaceuticals Inc
CEOKazley (Michael John)
Websitehttps://novabay.com/
KeyAI